METHOD FOR PREDICTING RISK OF DEATH AT HOSPITAL STAGE IN PATIENTS WITHOUT ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION WHO HAVE UNDERGONE NEW COVID-19 CORONAVIRUS INFECTION, TAKING INTO ACCOUNT THEIR IMMUNOLOGICAL STATUS Russian patent published in 2022 - IPC A61B5/245 G01N33/49 G01N33/53 G01N33/70 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely cardiology, and can be used to predict the risk of death at the hospital stage in patients with myocardial infarction without ST-segment elevation (MIweST) who have undergone COVID-19. The gender and age of the patient are determined, anamnestic data is analyzed, laboratory tests are performed, including clinical and biochemical blood analysis, glomerular filtration rate is calculated, serological examination of IgG antibody titer to SARS-CoV-2 is performed, ECG is measured and risks are calculated on the GRACE 1.0 scale. Then, according to the calculation formula, the probability of the risk of death (P) at the hospital stage is calculated. With a value of P≥0.110, a high risk of death in a patient with MIweST is predicted, with a value of P <0.110, a low risk of death in a patient with MIweST is predicted.

EFFECT: invention makes it possible to increase the accuracy of predicting the risk of death at the hospital stage in patients with MIweST, taking into account the previously transferred COVID-19 and indirect signs of the severity of the immunological response - an increase in the IgG titer to SARS-CoV-2 in peripheral venous blood by evaluating the totality of the most significant indicators.

1 cl, 1 dwg, 1 tbl, 2 ex